Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Publication
- Publication Type
Articles 1 - 8 of 8
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
The Potential Of Herbal Combinations As Adjunctive Therapy For Standard Care Of Covid-19 Patients: A Lesson Learned From Indonesia, Anna Rozaliyani, Satria Pratama, Findra Setianingrum, Fenny Yunita, C. Martin Rumende
The Potential Of Herbal Combinations As Adjunctive Therapy For Standard Care Of Covid-19 Patients: A Lesson Learned From Indonesia, Anna Rozaliyani, Satria Pratama, Findra Setianingrum, Fenny Yunita, C. Martin Rumende
Pharmaceutical Sciences and Research
The pandemic of novel coronavirus disease (COVID-19) has become a global disaster that occurred between the end of 2019 and 2023. It caused immeasurable damage to almost all aspects of human life. The disease has opened a lot of new perspectives on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) origins and pathogenesis, the nature of the virus, the potential for new treatments, and new policies to overcome this pandemic. This review aims to know the potential of plants that are beneficial to combat the diseases, including immunomodulators in the management of COVID-19. Studies reporting COVID-19 with the keywords SARS-CoV-2, COVID-19, …
The Effects Of Clonidine On Neonatal Abstinence Syndrome Patient Outcomes, Claire E. Flatt
The Effects Of Clonidine On Neonatal Abstinence Syndrome Patient Outcomes, Claire E. Flatt
Chancellor’s Honors Program Projects
No abstract provided.
Discovery Of Ojt010 As A Novel Inhibitor Of Severe Acute Respiratory Syndrome Coronavirus 2, Manvir Kaur
Discovery Of Ojt010 As A Novel Inhibitor Of Severe Acute Respiratory Syndrome Coronavirus 2, Manvir Kaur
Dissertations (2016-Present)
The current pandemic of coronavirus disease (COVID-19) caused by the highly infectious pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents a global public health challenge. The emergence of deadly SARS-CoV-2 variants with mutations on the viral genes has made it more imperative to discover therapeutics that target the host receptors for COVID-19 treatment. Therefore, our research has targeted the critical host entry receptors: Angiotensin-converting enzyme-2 (ACE2) for SARS-CoV-2 entry into the human cells. SARS-CoV-2 is an enveloped RNA beta coronavirus that infects human cells via interaction with the ACE2 receptor, followed by viral replication and virus dissemination. Spike protein …
Nanoparticle-Mediated Drug Delivery For The Treatment Of Cardiovascular Diseases, Rajasekharreddy Pala, Vt Anju, Madhu Dyavaiah, Siddhardha Busi, Surya M. Nauli
Nanoparticle-Mediated Drug Delivery For The Treatment Of Cardiovascular Diseases, Rajasekharreddy Pala, Vt Anju, Madhu Dyavaiah, Siddhardha Busi, Surya M. Nauli
Pharmacy Faculty Articles and Research
Cardiovascular diseases (CVDs) are one of the foremost causes of high morbidity and mortality globally. Preventive, diagnostic, and treatment measures available for CVDs are not very useful, which demands promising alternative methods. Nanoscience and nanotechnology open a new window in the area of CVDs with an opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues. The application of nanoparticles and nanocarriers in the area of cardiology has gathered much attention due to the properties such as passive and active targeting to the cardiac tissues, improved target specificity, and sensitivity. It has reported that more than …
Actionable Patient Safety Solution (Apss) #3c: Improve Prevention Of Severe Hypoglycemia, Jerika Lam, Steven Barker, Michael Ramsay, Ariana Longley, Joe Kiani
Actionable Patient Safety Solution (Apss) #3c: Improve Prevention Of Severe Hypoglycemia, Jerika Lam, Steven Barker, Michael Ramsay, Ariana Longley, Joe Kiani
Pharmacy Faculty Articles and Research
This report presents a plan of action for introducing a "program to reduce errors in the recognition and treatment of [severe hypoglycemia]".
Advancements In Treatment For Sensorineural Hearing Loss: Implications For Rehabilitation Professionals, Shawn P. Saladin, Yasar Tasnif, Bianca Cruz, Robert B. Perez
Advancements In Treatment For Sensorineural Hearing Loss: Implications For Rehabilitation Professionals, Shawn P. Saladin, Yasar Tasnif, Bianca Cruz, Robert B. Perez
JADARA
Rehabilitation professionals often work with individuals with sensorineural hearing loss. Sometimes the hearing loss is due to ototoxic medications that are prescribed as treatments for other conditions. An understanding of the types of ototoxic medications at the root of the sensorineural hearing loss combined with an understanding of the advancements in treatments will help the rehabilitation professional better serve consumers who fit this description.
Comparing The 2013 Acc/Aha & 2014 Nla Dyslipidemia Guidelines And Their Impact On Clinical Decision Making, Alexander Forbes, Kevin Grimes, Jocelyn York, Laura Tsu
Comparing The 2013 Acc/Aha & 2014 Nla Dyslipidemia Guidelines And Their Impact On Clinical Decision Making, Alexander Forbes, Kevin Grimes, Jocelyn York, Laura Tsu
Pharmacy Faculty Articles and Research
This home-study CPE activity has been developed to educate pharmacists on the similarities and differences between the 2014 NLA Recommendations for Dyslipidemia Management and the 2013 ACC/AHA Guidelines for Treatment of Blood Cholesterol.
Outpatient Administration Of Paclitaxel, Siu Fun Wong
Outpatient Administration Of Paclitaxel, Siu Fun Wong
Pharmacy Faculty Articles and Research
Paclitaxel (Taxol®, Bristol-Meyers Squibb), anti neoplastic agent made from the bark of the Pacific yew tree, is undoubtedly one of the most exciting agents to be evaluated over the past decade. Paclitaxel has demonstrated significant promise against ovarian and metastatic breast cancer, and appears to be the most effective single agent to date for non-small-cell lung cancer in trials conducted by Eastern Cooperative Oncology Group (ECOG).